BenevolentAI is a clinical-stage AI-enabled drug discovery company, actively working to transform the landscape of pharmaceutical development. By integrating advanced AI capabilities with scientific expertise and wet-lab facilities, BenevolentAI aims to identify and develop novel drug candidates more effectively than traditional methods. The BenevolentAI Platform™ supports a diverse pipeline of over 20 disease programs, advancing from target discovery to clinical studies, in collaboration with major partners like AstraZeneca and various research institutions. The company's commitment to inclusivity is reflected in its diverse workforce, representing over 35 nationalities and a broad range of backgrounds, fostering an environment where individuals can contribute authentically. BenevolentAI is headquartered in London, with additional offices in Cambridge and New York, consistently striving to improve patient outcomes through innovation in drug discovery.